UNSPSC 51152030: Fenyramidol or phenyramidol

This classification denotes a muscle relaxant with the molecular formula C13H14N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R3V02WL7O3, chemically known as benzyl alcohol, .alpha.-(2-pyridyl-aminomethyl)-, hydrochloride but generally known as fenyramidol, which bears US NIH Compound Identifier 9470. European Medicines Agency schedules Fenyramidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07602MIG.

UNSPSC 51152030 Fenyramidol or phenyramidol is a Commodity code that does not align with the state and local procurement activity currently tagged under it. The recent opportunities in the block are soliciting naloxone (an opioid antagonist used for overdose reversal), safe drug deactivation systems, and pharmaceutical benefit management services — none of which fall within the scope of fenyramidol, a nonsteroidal anti-inflammatory drug used in musculoskeletal pain management. The mismatch suggests either a classification error in the procurement records or a misalignment between the code's nominal scope and how state and local jurisdictions are applying it in practice. State and local governments do procure pharmaceuticals and medical supplies through health departments, county health agencies, and state health and human services commissions, but the recent postings under this code do not reflect purchases of fenyramidol itself.

Seminole County, Florida issued IFB60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, and the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for its Therapeutic Pharmacy Initiative. Neither opportunity reflects fenyramidol procurement or reflects the Commodity code's intended scope. Without recent solicitations for fenyramidol itself, this code shows little relevant activity for vendors focused on that pharmaceutical product line.